Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Open accessThe DOI matches its Crossref record; 105 of the 124 references it cites were found in a registry or an index.
Abstract
Camptothecins are broad-spectrum anticancer drugs that specifically target DNA topoisomerase I (Topo I). The formation of a cleavable drug-Topo I-DNA complex results in lethal double-strand DNA breakage and cell death. However, de novo or acquired clinical resistance to camptothecins is common. Studies of the camptothecin analog irinotecan suggest the following general mechanisms of resistance: (i) variable levels of the enzymes involved in the conversion of irinotecan; (ii) reduced cellular accumulation from active drug efflux; (iii) reduced levels of Topo I expression; (iv) alterations in the structure of Topo I from different mutations; (v) alterations in the cellular response to camptothecin-Topo I-DNA complex formation, which involves proteasome degradation of Topo I and/or enhanced DNA repair; and (vi) activation of the transcription factor nuclear factor kappa B by DNA damage and subsequent suppression of apoptosis. Multiple approaches using pharmacological and biological modulation to circumvent the above mechanisms of resistance have been incorporated into ongoing clinical trials and are expected to enhance the antitumor activity of irinotecan and reduce its systemic toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Carboxylesterase 2 (CES2) is the critical enzyme for the activation of irinotecan, which can catalyze the conversion of irinotecan to the more active form of SN-38 (a topoisomerase inhibitor) [88].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [88]
In the citing paper
“In addition, the amount of TOP-1 bound to DNA is reduced, which may also lead to CRC resistance to irinotecan [88,131].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 4,979
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 1×
“Initial approval in the United States was as a second-line treatment for metastatic colorectal cancer, after failure of 5-fluorouracil (5-FU) and leucovorin [2], and more recently it has been approved for use in combination with 5-FU/leucovorin as a first-line treatment for this disease [3, 4].”
BackgroundAn Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003034 · Cited by 1,371
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Research works printed but not linked: 8
- Ilson D, Enzinger P, Saltz L et al. Phase II trial of weekly irinotecan + cisplatin in advanced gastric cancer. Proc Am Soc Clin Oncol 1999; 18: 259a (Abstr).
- Hecht JR. Gastrointestinal toxicity of irinotecan. Oncology 1998; 12: 72-78.
- Prados M, Kuhn J, Yung W et al. A phase-I study of CPT-11 given every 3 weeks to patients with recurrent malignant glioma. A North American Brain Tumor Consortium (NABTC) study. Proc Am Soc Clin Oncol 2001; 19: 162 (Abstr 627).
- Kameyama M, Shoichi I, Ohtsuka K et al. Activation and detoxifica- tion of CPT-11 by human lung cancer cells. Proc Am Soc Clin Oncol 2000; 19: 505a (Abstr 1975).
- Villalona-Calero MA, Kuhn JG, Drengler R et al. Pharmaco- logically-based phase I study of mitomycin C (MMC) as a modulator of irinotecan (CPT-11) antitumor activity. Proc Am Soc Clin Oncol 2001; 20: 101a (Abstr 400).
- Kolesar J, Miller J, Duan W, Villalona-Calero M. TI induction in PBMC by mitomycin-C predicts irinotecan response. Proc Am Soc Clin Oncol 2002; 21: 115 (Abstr 456).
- Ratain, 1999, A phase I study of irinotecan (CPT-11) with pharmacokinetic modulation by cyclosporine A (CSA) and phenobarbital (PB), Proc Am Soc Clin Oncol, 18, 202a
- Takeda, 2001, Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients, Int J Cancer, 92, 269, 10.1002/1097-0215(200102)9999:9999<::AID-IJC1179>3.0.CO;2-3 · DOI · Paper page
Cited by
Items 101–200 of 419
Zheng, S., Wang, J., Ding, N., Chen, W., Chen, H.-D., Xue, M., Chen, F., Ni, J., Wang, Z., Lin, Z., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01127-5 · Cited by 52
Woźniak, M., Makuch, S., Winograd, K., Wiśniewski, J. Ł., Ziolkowski, P. P., & Agrawal, S. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-02913-8 · Cited by 50
Emerging targets in cancer drug resistance
Kumar, S., Kushwaha, P. P., & Gupta, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2018.27 · Cited by 52
Sun, F., Liang, W., & Qian, J. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10588 · Cited by 50
Sharma, V., Lansdell, T. A., Peddibhotla, S., & Tepe, J. J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.10.006 · Cited by 51
Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us
Kumar, S., & Sherman, M. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087233 · Cited by 50
Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer
Reynolds, I. S., O’Connell, E., Fichtner, M. W., McNamara, D. A., Kay, E. W., Prehn, J. H. M., Furney, S. J., & Burke, J. P. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0137-6 · Cited by 51
Byun, W. S., Kim, S., Shin, Y., Kim, W. K., Oh, D., & Lee, S. K. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00918 · Cited by 45
Liu, Z., Li, H., Derouet, M. F., Berezkin, A., Sasazuki, T., Shirasawa, S., & Rosen, K. V. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508664200 · Cited by 47
Caponigro, F., Formato, R., Caraglia, M., Normanno, N., & Iaffaioli, R. V. (2005) · Current Opinion in Oncology · doi:10.1097/01.cco.0000159623.68506.cf · Cited by 46
Byun, W. S., Bae, E. S., Kim, W. K., & Lee, S. K. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.2c00224 · Cited by 46
Quackenbush, K. S., Bagby, S., Tai, W. M., Messersmith, W. A., Schreiber, A., Greene, J., Kim, J., Wang, G., Purkey, A., Pitts, T. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8626 · Cited by 43
Extracellular vesicles as modifiers of antibody‐drug conjugate efficacy
Barok, M., Puhka, M., Yazdi, N., & Joensuu, H. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12070 · Cited by 42
The effective combination therapies with irinotecan for colorectal cancer
Chai, Y., Liu, J., Zhang, S., Li, N., Xu, D., Liu, W., Fu, R., & Tang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1356708 · Cited by 55
Wang, D.-F., Rong, W.-T., Yu, L., Hou, J., Qi, S., Xiao, Q., Zhang, J., You, J., Yu, S., & Xu, Q. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/am508340m · Cited by 42
Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity
Hahn, R. Z., Antunes, M. V., Verza, S. G., Perassolo, M. S., Suyenaga, E. S., Schwartsmann, G., & Linden, R. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180622141101 · Cited by 45
Liu, R., Sun, M., Zhang, G., Lan, Y., & Yang, Z. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.09.065 · Cited by 47
Li, J., Kuang, Y., Shi, J., Zhou, J., Medina, J. E., Zhou, R., Yuan, D., Yang, C., Wang, H., Yang, Z., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201507157 · Cited by 45
De-coding the complex role of microbial metabolites in cancer
Escriva, P. P., Bernardino, C. C. T., & Letellier, E. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115358 · Cited by 54
ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan
Tuy, H. D., Shiomi, H., Mukaisho, K. I., Naka, S., Shimizu, T., Sonoda, H., Mekata, E., Endo, Y., Kurumi, Y., Sugihara, H., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4937 · Cited by 41
Derouet, M. F., Wu, X., May, L. L., Yoo, B. H., Sasazuki, T., Shirasawa, S., Rake, J., & Rosen, K. V. (2007) · Neoplasia · doi:10.1593/neo.07217 · Cited by 42
Sun, M., Tian, X., & Yang, Z. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b01746 · Cited by 44
A short update on cancer chemoresistance
Hamilton, G., & Rath, B. (2014) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-014-0311-z · Cited by 44
McQuade, R. M., Stojanovska, V., Donald, E. L., Rahman, A. A., Campelj, D. G., Abalo, R., Rybalka, E., Bornstein, J. C., & Nurgali, K. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00391 · Cited by 38
Multifunctional Role of Astrocyte Elevated Gene-1 (AEG-1) in Cancer: Focus on Drug Resistance
Manna, D., & Sarkar, D. (2021) · Cancers · doi:10.3390/cancers13081792 · Cited by 40
St. John’s Wort Modulates the Toxicities and Pharmacokinetics of CPT-11 (Irinotecan) in Rats
Hu, Z., Yang, X., Ho, P. C., Chan, E., Chan, S. Y., Xu, C., Li, X., Zhu, Y. Z., Duan, W., Chen, X., et al. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-4585-0 · Cited by 37
Takeba, Y., Sekine, S., Kumai, T., Matsumoto, N., Nakaya, S., Tsuzuki, Y., Yanagida, Y., Nakano, H., Asakura, T., Ohtsubo, T., et al. (2007) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.30.1400 · Cited by 38
Molecular signalling pathways in canine gliomas
Boudreau, C. E., York, D. S., Higgins, R. J., LeCouteur, R. A., & Dickinson, P. J. (2015) · Veterinary and Comparative Oncology · doi:10.1111/vco.12147 · Cited by 43
Liu, X., & Hummon, A. B. (2015) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-014-1071-0 · Cited by 41
Sharma, A. R., Vatapalli, R. J., Abdelfatah, E., McMahon, K. W., Kerner, Z. J., Guzzetta, A. A., Singh, J., Zahnow, C. A., Baylin, S. B., Yerram, S. R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176139 · Cited by 38
Qiu, P., Zhang, S., Zhou, Y., Zhu, M., Kang, Y., Chen, D., Wang, J., Zhou, P., Li, W., Xu, Q., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.022 · Cited by 36
Elsalem, L., Jum’ah, A. A., Alfaqih, M. A., & Aloudat, O. (2020) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s243337 · Cited by 39
Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail?
Gieseler, F., Rudolph, P., Kloeppel, G., & Fölsch, U. R. (2003) · International Journal of Colorectal Disease · doi:10.1007/s00384-003-0496-x · Cited by 36
Temmink, O. H., Hoebe, E. K., Fukushima, M., & Peters, G. J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.08.022 · Cited by 39
Zeynali-Moghaddam, S., Mohammadian, M., Kheradmand, F., Azarbayjani, A. F., Rasmi, Y., Esna-Ashari, O., & Malekinejad, H. (2018) · Gene · doi:10.1016/j.gene.2018.10.016 · Cited by 35
Synthesis and Biological Potentials of Quinoline Analogues: A Review of Literature
Kumari, L., Salahuddin, S., Mazumder, A., Pandey, D., Yar, M. S., Kumar, R., Mazumder, R., Sarafroz, M., Ahsan, M. J., Kumar, V., et al. (2019) · Mini-Reviews in Organic Chemistry · doi:10.2174/1570193x16666190213105146 · Cited by 38
Gao, J., Nesbitt, H., Logan, K. A., Burnett, K. M., White, B. C., Jack, I. G., Taylor, M., Love, M., Callan, B., McHale, A. P., et al. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.10.012 · Cited by 36
Sun, M., Chen, X., & Yang, Z. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.339761 · Cited by 41
Developmental origins shape the paediatric cancer genome
Chen, X., Yang, W., Roberts, C. W. M., & Zhang, J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00684-9 · Cited by 56
Proia, D. A., Smith, D. L., Zhang, J., Jimenez, J.-P., Sang, J., Ogawa, L. S., Sequeira, M., Acquaviva, J., He, S., Zhang, C., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0455 · Cited by 36
Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer
Chao, J., Lin, J. L., Frankel, P. H., Clark, A. J., Wiley, D. T., Garmey, E. G., Fakih, M., Lim, D. W., Chung, V. M., Luevanos, E., et al. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.08.10 · Cited by 34
Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment
Dopeso, H., Mateo‐Lozano, S., Élez, E., Landolfi, S., Ramos, F. J., Hernández‐Losa, J., Mazzolini, R., Rodrigues, P., Bazzocco, S., Carreras, M. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3275 · Cited by 33
The Pivotal Player: Components of NF-κB Pathway as Promising Biomarkers in Colorectal Cancer
Martin, M., Sun, M., Motolani, A., & Lu, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147429 · Cited by 36
LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan
Fakhr, E., Zare, F., Azadmanesh, K., & Teimoori‐Toolabi, L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112091 · Cited by 37
Tanaka, K., Okigami, M., Toiyama, Y., MORIMOTO, Y., Matsushita, K., Kawamura, M., Hashimoto, K., Saigusa, S., Okugawa, Y., Inoue, Y., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.1983 · Cited by 33
The Effectiveness of Various Chemotherapeutic Agents in Cancer Treatment
Fathima, J. K., LAVANYA, V. A., Jamal, S., & Ahmed, N. (2022) · Current Pharmacology Reports · doi:10.1007/s40495-022-00289-6 · Cited by 33
Yuan, M., Chen, T., Lu, J., Zhang, P., Xie, L., Zhou, S., Fan, L., Wang, L., Zhang, C., Tang, N., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02157-x · Cited by 34
Ma, Y., Han, W., Li, J., Hu, L., & Zhou, Y. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.157 · Cited by 36
Gholam, D., Chebib, A., Hauteville, D., Bralet, M., & Jasmin, C. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3280adc8e0 · Cited by 32
Shen, J., Wei, J., Wang, H., Yue, G., Yu, L., Yang, Y., Xie, L., Zou, Z., Qian, X., Ding, Y., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-73 · Cited by 32
Self-assembled polypeptide nanoparticles for intracellular irinotecan delivery
Zashikhina, N., Volokitina, M. V., Korzhikov-Vlakh, V. A., Tarasenko, I. I., Lavrentieva, A. V., Scheper, T. H., Rühl, E., Орлова, Р. В., Tennikova, T. B., & Korzhikova‐Vlakh, E. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.07.022 · Cited by 32
Yoo, B. H., Wu, X., Derouet, M. F., Haniff, M., Eskelinen, E., & Rosen, K. V. (2009) · Autophagy · doi:10.4161/auto.5.8.10167 · Cited by 33
Zhang, Y., Li, Y., Sun, C., Chen, X., Han, L., Wang, T., Liu, J., Chen, X., & Zhao, D. (2021) · Cancers · doi:10.3390/cancers13164002 · Cited by 31
Tumour cells resistance in cancer therapy
Martínez-Lacaci, I., García-Morales, P., Soto, J. L., & Saceda, M. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0004-9 · Cited by 31
Irinotecan Toxicity to Human Blood Cells in vitro: Relationship between Various Biomarkers
Kopjar, N., Želježić, D., Vrdoljak, A. L., Radić, B., Ramić, S., Milić, M., Gamulin, M., Pavlica, V., & Fučić, A. (2007) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2007.00068.x · Cited by 31
Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line
Wu, Z., Yang, Y., Zeng, L., Patel, H. H., Bo, L., Lin, L., & Chen, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.624954 · Cited by 38
Fenouille, N., Grosso, S., Yunchao, S., Mary, D. A. S. G., Pontier-Bres, R., Imbert, V., Czerucka, D., Caroli‐Bosc, F., Peyron, J., & Lagadec, P. (2011) · The Journal of Pathology · doi:10.1002/path.3034 · Cited by 30
Comparative studies on the interaction of anticancer drug irinotecan with dsDNA and ssDNA
Temerk, Y. M., Ibrahim, M., Ibrahim, H., & Schuhmann, W. W. (2018) · RSC Advances · doi:10.1039/c8ra03231a · Cited by 29
Kang, J. H., Lee, K.-H., Kim, D., Kim, S.-W., Kim, H. R., Kim, J.-H., Choi, J.-H., An, H. J., Kim, J.-S., Jang, J.-S., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01055-5 · Cited by 29
Li, Y., Xie, M., Jones, J. B., Zhang, Z., Wang, Z., Dang, M. T., Wang, X., Lipowska, M., & Mao, H. Z. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102816 · Cited by 37
Braun, A., Stark, K., Dirsch, O., Hilger, R. A., Seeber, S., & Vanhoefer, U. J. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200511000-00009 · Cited by 32
Chen, M., Lee, N., Ho, T., Hsu, H.-H., Kuo, C., Kuo, W., Lin, Y.-M., Tsai, F., Tsai, C., & Huang, C. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.023 · Cited by 28
Role of Ginseng, Quercetin, and Tea in Enhancing Chemotherapeutic Efficacy of Colorectal Cancer
Zhao, L., Zhao, H., Zhao, Y., Sui, M., Liu, J., Li, P., Liu, N., & Zhang, K. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.939424 · Cited by 29
Jayanthan, A., Bernoux, D., Bose, P., Riabowol, K. T., & Narendran, A. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-44 · Cited by 27
Thetchinamoorthy, K., Kuo, W., Chen, M., Viswanadha, V. P., Shen, C.-Y., Tu, C., Yeh, Y., Bharath, M., Shibu, M. A., & Huang, C. (2020) · Cancers · doi:10.3390/cancers12051231 · Cited by 28
Assembly of Glycopeptides in Living Cells Resembling Viral Infection for Cargo Delivery
Tian, F., Guo, R., Wu, C., Liu, X., Zhang, Z., Wang, Y., Wang, H., Li, G., & Yu, Z. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202404703 · Cited by 27
Targeted Therapy in Nonmelanoma Skin Cancers
Spallone, G., Botti, E., & Costanzo, A. (2011) · Cancers · doi:10.3390/cancers3022255 · Cited by 26
Liang, G.-B., Yu, Y.-C., Wei, J.-H., Kuang, W., Chen, Z., & Zhang, Y. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.112033 · Cited by 26
Lagadec, P., Griessinger, E., Nawrot-Esposito, M.-P., Fenouille, N., Colosetti, P., Imbert, V., Mari, M., Hofman, P. M., Czerucka, D., Rousseau, D., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604082 · Cited by 26
Anticancer effect of SZC017, a novel derivative of oleanolic acid, on human gastric cancer cells
Gao, L., Xu, Z., WANG, Y., Sun, B., Song, Z., YANG, B., Liu, X., Lin, Y., Peng, J., Han, G., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.4447 · Cited by 25
Kailass, K., Sadovski, O., Zipfel, W. R., & Beharry, A. A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01965 · Cited by 26
Tang, W., Su, G., Li, J., Liao, J., Chen, S., Huang, C., Liu, F., Chen, Q., & Ye, Y. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2513 · Cited by 27
A review on Stimuli-pH responsive liposomal formulation in cancer therapy
Jayapriya, P., Pardhi, E., Vasave, R., Guru, S. K., Madan, J., & Mehra, N. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105172 · Cited by 24
Motlagh, N. S. H., Parvin, P., Ghasemi, F., Atyabi, F., Jelvani, S., & Abolhosseini, S. (2016) · Laser Physics Letters · doi:10.1088/1612-2011/13/7/075604 · Cited by 24
Kalthoff, S., Paulusch, S., Rupp, A. B. A., Holdenrieder, S., Hartmann, G., & Strassburg, C. P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15162 · Cited by 24
Bhutiani, N., Li, Y., Zheng, Q., Pandit, H., Shi, X., Chen, Y., Yu, Y., Pulliam, Z., Tan, M., & Martin, R. C. G. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08782-2 · Cited by 24
Ginghină, O., Hudiță, A., Zaharia, C., Tsatsakis, A. M., Mezhuev, Y. O., Costache, M., & Gălățeanu, B. (2021) · Materials · doi:10.3390/ma14092440 · Cited by 25
SENP1 participates in Irinotecan resistance in human colon cancer cells
Chen, M., Nhan, D. C., Hsu, C.-H., Wang, T., Li, C., Ho, T., Mahalakshmi, B., Chen, M., Yang, L., & Huang, C. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29946 · Cited by 26
Synergistic Effects of Irinotecan and Flavonoids on Ehrlich Ascites Tumour-Bearing Mice
Knežević, A. H., Đikić, D., Lisičić, D., Kopjar, N., Oršolić, N., Karabeg, S., & Benković, V. (2011) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00735.x · Cited by 25
Woo, J. K., Kang, J., Kim, B., Park, B. H., Shin, K.-J., Song, S.-W., Kim, J. J., Kim, H., Lee, S.-J., & Oh, S. H. (2015) · Oncotarget · doi:10.18632/oncotarget.4369 · Cited by 25
Takara, K., Kitada, N., Yoshikawa, E., Yamamoto, K., Horibe, S., Sakaeda, T., Nishiguchi, K., Ohnishi, N., & Yokoyama, T. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.12.033 · Cited by 24
Huang, T. H., Chen, H.-C., Chou, S.-M., Yang, Y. S. H., Fan, J.-R., & Li, T. (2010) · Cell Research · doi:10.1038/cr.2010.95 · Cited by 28
Wang, H., Bai, H., Wang, J., Zhou, X., Chen, H., Wang, L., Ren, H., Liu, Z., Zhuo, W., Zhou, Z., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121458 · Cited by 25
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Gibson, C. R., Sandhu, P., & Hanley, W. D. (2009) · Wiley eBooks · doi:10.1002/9780470485408.ch19 · Cited by 23
Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back
Rossi, V., Turati, A., Rosato, A., & Carpanese, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1447280 · Cited by 25
Carr, J. S., King, S., & Dekaney, C. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173429 · Cited by 22
Gupta, V., Falciani, F., Layman, B. R., Hill, M. L., Rapino, S., & Dick, J. E. (2025) · Chemical & Biomedical Imaging · doi:10.1021/cbmi.4c00105 · Cited by 25
Jassi, C., Kuo, W., Chang, Y.-C., Wang, T., Li, C., Ho, T., Hsieh, D. J., Kuo, C., Chen, M., & Huang, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115911 · Cited by 25
Granot, T., & Meruelo, D. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.33 · Cited by 21
Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells
Gao, K., LOCKWOOD, W., Li, J., Lam, W., & Li, G. (1992) · International Journal of Oncology · doi:10.3892/ijo_32_6_1343 · Cited by 25
Desbois, N., Pertuit, D., Moretto, J., Cachia, C., Chauffert, B., & Bouyer, F. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.09.037 · Cited by 21
Hu, Y., Zhang, Y., Wang, X., Jiang, K., Wang, H., Yao, S., Liu, Y., Lin, Y.-Z., Wei, G., & Lu, W. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00052 · Cited by 20
Kontek, R., Drozda, R., Śliwiński, M., & Grzegorczyk, K. (2009) · Toxicology in Vitro · doi:10.1016/j.tiv.2009.10.013 · Cited by 23
Lewis, A. L., & Hall, B. C. (2019) · Future Oncology · doi:10.2217/fon-2019-0071 · Cited by 19
Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group
On behalf of the EORTC PAMM Group, Perego, P., Hempel, G., Linder, S. T., Bradshaw, T. D., Larsen, A. K., Peters, G. J., & Phillips, R. M. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3502-7 · Cited by 20
The Role of Plant Metabolites in Drug Discovery: Current Challenges and Future Perspectives
Anwar, N., Teo, Y. K., & Tan, J. B. L. (2019) · Springer eBooks · doi:10.1007/978-981-13-7205-6_2 · Cited by 25
Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies
du Toit‐Thompson, T., Leck, L. Y. W., Gillson, J., Pavlakis, N., Gill, A. J., Samra, J. S., Mittal, A., & Sahni, S. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115647 · Cited by 22
The role of cetuximab in the treatment of metastatic colorectal cancer.
Holubec, L., Liška, V., Matějka, V. M., Fiala, O., Dreslerova, J., Mrázková, P., Třeška, V., & Fínek, J. (2012) · PubMed · Cited by 18
Gawley, M., Almond, L., Daniel, S., Lastakchi, S., Kaur, S., Detta, A., Cruickshank, G. S., Miller, C. R., Hingtgen, S., Sheets, K., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.012 · Cited by 18
Ren, S.-N., Zhang, Z.-Y., Guo, R.-J., Wang, D., Chen, F., Chen, X., & Fang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i13.1911 · Cited by 22
Metadata
- Authors
- Xu, Y., & Villalona-Calero, M. A.
- Affiliations
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Corresponding author
- Villalona-Calero, M.A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2002-12
- Volume
- 13
- Issue
- 12
- Pages
- 1841-1851
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2112055293
- Cited by
- 413
- References
- 124
- Citations by year
- 2026: 25 · 2025: 18 · 2024: 25 · 2023: 40 · 2022: 30 · 2021: 23 · 2020: 24 · 2019: 17 · 2018: 16 · 2017: 22 · 2016: 15 · 2015: 24 · 2014: 13 · 2013: 11 · 2012: 10
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 6246 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Texas Health Science Center at San Antonio
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, camptothecin, topoisomerase I, drug resistance, drug efflux, proteasomal degradation, DNA repair, NF-κB, apoptosis, anticancer drug metabolism, combination therapy
- MeSH terms
- Irinotecan, Animals, Camptothecin, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Neoplasms, Sensitivity and Specificity, NF-kappa B, Apoptosis, Risk Assessment, Drug Resistance, Neoplasm, Maximum Tolerated Dose, Topoisomerase I Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.